|
gptkbp:instanceOf
|
gptkb:drug
antihistamine
|
|
gptkbp:approvedBy
|
1956
|
|
gptkbp:ATCCode
|
N05BB01
|
|
gptkbp:availableOn
|
gptkb:sugar
gptkb:tablet
capsule
solution for injection
|
|
gptkbp:brand
|
gptkb:Atarax
gptkb:Vistaril
|
|
gptkbp:CASNumber
|
2192-20-3
|
|
gptkbp:contraindication
|
hypersensitivity
prolonged QT interval
pregnancy (first trimester)
|
|
gptkbp:crossesBloodBrainBarrier
|
yes
|
|
gptkbp:developedBy
|
gptkb:Union_Chimique_Belge
|
|
gptkbp:drugClass
|
first-generation antihistamine
piperazine derivative
|
|
gptkbp:excretion
|
kidneys
|
|
gptkbp:hasMolecularFormula
|
C21H27ClN2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Hydroxyzine
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:CNS_depressants
anticholinergic drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
H1 receptor antagonist
anticholinergic effects
anxiolytic effects
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
intravenous use
|
|
gptkbp:overdoseSymptoms
|
seizures
CNS depression
cardiac arrhythmias
|
|
gptkbp:pregnancyCategory
|
US: D
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:prodrugOf
|
gptkb:cetirizine
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
|
|
gptkbp:sideEffect
|
confusion
dizziness
headache
drowsiness
dry mouth
urinary retention
|
|
gptkbp:usedFor
|
nausea
anxiety
pruritus
insomnia
sedation
allergy symptoms
|
|
gptkbp:bfsParent
|
gptkb:Anti-Anxiety_Agents
gptkb:R06AE
|
|
gptkbp:bfsLayer
|
7
|